NCT02412371 - A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions

Non-small Cell Lung Cancer Stage III

Interventions

DRUG

Paclitaxel

Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

DRUG

Placebo for Veliparib

Capsule for oral administration

DRUG

Carboplatin

Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)

DRUG

Veliparib

Capsule for oral administration

RADIATION

Radiotherapy

Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks

Trial Locations (12)

13210

SUNY Upstate Medical University - Downtown /ID# 133492, Syracuse

19713

Christiana Care Health Service /ID# 133486, Newark

21201

Univ Maryland School Medicine /ID# 132944, Baltimore

22908

University of Virginia /ID# 133495, Charlottesville

27157

Wake Forest Univ HS /ID# 134608, Winston-Salem

27599

Unc /Id# 133496, Chapel Hill

92093

Ucsd /Id# 133037, La Jolla

60637-1443

University of Chicago /ID# 133828, Chicago

02215

Dana-Farber Cancer Institute /ID# 133494, Boston

27710-3000

Duke University Medical Center /ID# 133497, Durham

02903

Rhode Island Hospital /ID# 133493, Providence

02906

The Miriam Hospital /ID# 133910, Providence